Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase

Kostelník, Adam; Cegan, Alexander; Pohanka, Miroslav

doi:10.1155/2017/2532764

Cited by 22 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used biperidine as a standard molecule for docking. Biperidine was published in the literature and shown to have -7.9 kCalmol -1 [37]. In our present studies, we also got similar binding energy.…”

Section: Resultssupporting

confidence: 87%

Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors

Patil

Sistla

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Among neurodegenerative diseases, Alzheimer’s disease (AD) is one of the most grievous disease. The oldest cholinergic hypothesis is used to elevate the level of cognitive impairment and acetylcholinesterase (AChE) comprises the major targeted enzyme in AD. Thus, acetylcholinesterase inhibitors (AChEI) constitutes the essential remedy for the treatment of AD. The study aims to evaluate the interactions between natural molecules and AChE by Surface Plasmon Resonance (SPR). The molecules like alkaloids, polyphenols and substrates of AChE have been considered for the study with a major emphasis on affinity and kinetics. To better understand the activity of small molecules, the investigation is supported by both experimental and theoretical approach such as fluorescence, Circular Dichroism (CD) and molecular docking studies. Amongst the screened ones tannic acid showed promising results compared with others. The methodology followed here have highlighted many molecules with a higher affinity towards AChE and these findings may take lead molecules generated in preclinical studies to treat neurodegenerative diseases. Additionally, we suggest a unique signature for the heterogeneous analyte model using competitive experiments for analyzing simultanous interactions of both the analytes.

show abstract

Section: Resultssupporting

confidence: 87%

Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors

Patil

Sistla

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Biperiden is another muscarinic receptor antagonist with high affinity for the M 1 subtype used in the treatment of PD and neuroleptic-induced extrapyramidal motor side effects. Recently, it has also been demonstrated to behave as a weak inhibitor of acetylcholinesterase [295].…”

Section: Cholinergic Receptorsmentioning

confidence: 99%

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

et al. 2019

View full text Add to dashboard Cite

Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as well as transient elevated liver enzyme levels. Moreover, LD therapy leads to LD-induced dyskinesia (LID), a disabling motor complication that represents a major challenge for the clinical neurologist. Due to the many limitations associated with LD therapeutic use, other dopaminergic and non-dopaminergic drugs are being developed to optimize the treatment response. This review focuses on recent investigations about non-dopaminergic central nervous system (CNS) receptor ligands that have been identified to have therapeutic potential for the treatment of motor and non-motor symptoms of PD. In a different way, such agents may contribute to extending LD response and/or ameliorate LD-induced side effects.

show abstract

“… 9 Anticholinergic drugs have been also suggested to have anti-parkisonian effects. 10 These medications have benefucial effects on rgidity and tremor in PD patients. 11 In addition, antioxidant and anti-inflammatory agents have been shown to play a vital role in survival of neurons and alleviation of PD syptomes.…”

Section: Introductionmentioning

confidence: 99%

Effects of Medicinal Plants and Flavonoids on Parkinson's Disease, a Review on Basic and Clinical Evidences

2020

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disorder which is characterized by typical symptoms including gradual progressive muscle rigidity, tremor and loss of motor skills. Although there is no definitive cure for PD, the extract of some medicinal plants and their ingredients have been suggested to relieve its symptoms and to prevent disability in patients. This review is focused on therapeutic effects of some medicinal plants and their ingredients on PD. The findings presented in this review were collected from experimental and clinical studies in databases including PubMed, Web of Science and Google Scholar until the end of May 2019. The keywords "neurotoxicity " or "Parkinson’s disease" or "neuroprotective" and "Medicinal plants" and "Flavonoids" were searched. Based on the results of animal and clinical studies, the extract of medicinal plants and their components which are discussed in this review have neuro-protective effects against PD. These protective properties mainly are mediated through inhibition of dopamine metabolizing enzymes, reduction oxidant markers, increase of antioxidant agents and suppression of neuro-inflammation.

show abstract

Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase

Cited by 22 publications

References 30 publications

Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors

Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

Effects of Medicinal Plants and Flavonoids on Parkinson's Disease, a Review on Basic and Clinical Evidences

Contact Info

Product

Resources

About